DRG anticipates the next ten years to be a transitional time in the treatment of hemophilia A for patients with and without inhibitors. With the uptake of Roche / Chugai’s bispecific antibody Hemlibra and a diverse pipeline, both in terms of technology type and administration route, we forecast significant changes in disease management. The R&D emphasis has shifted to
will physicians treatinghemophilia A differentiate between the various emerging therapies, and which will gain the greatest market and patient share in an increasingly stringent regulatory environment?
- What clinical roles will Hemlibra,
fitusiran, concizumab, and gene therapy playin the evolving hemophilia A treatment landscape?
- How will the management of patients with inhibitors change when new treatment options become available? How will Hemlibra’s head start on its competitors play out over the forecast period?
- How will the factor VIII concentrate market evolve? How will
nonfactortreatment optionsimpact the multitude of brands vying for patient share in this space?
Disease Landscape & Forecast provides